Evonik Industries AG (ETR:EVK)
Germany · Delayed Price · Currency is EUR | Market Cap | 8.45B +11.4% |
| Revenue (ttm) | 14.11B -4.0% |
| Net Income | 121.00M -71.5% |
| EPS | 0.26 -71.7% |
| Shares Out | 466.00M |
| PE Ratio | 69.82 |
| Forward PE | 10.60 |
| Dividend | 1.00 (5.27%) |
| Ex-Dividend Date | Jun 4, 2026 |
| Volume | 1,276,879 |
| Open | 18.13 |
| Previous Close | 18.13 |
| Day's Range | 17.81 - 18.18 |
| 52-Week Range | 12.49 - 19.21 |
| Beta | 0.55 |
| Analysts | Hold |
| Price Target | 18.30 (+2.46%) |
| Earnings Date | Nov 3, 2026 |
About Evonik Industries AG
Evonik Industries AG operates as a chemicals company in the Asia-Pacific, Europe, the Middle East, Africa, and the Americas. It operates through the Advanced Technologies, Custom Solutions, and Infrastructure segments. The Advanced Technologies segment provides polymers for medical applications; crosslinkers; hydrogen peroxide, a sterilizing agent for cleaning silicon wafers and a bleaching agent for the paper and textile industries; fumed and precipitated silicas and silanes for the automotive, tire, electronics, and cosmetics industries; and ... [Read more]
Financial Performance
In 2025, Evonik Industries AG's revenue was 14.07 billion, a decrease of -7.18% compared to the previous year's 15.16 billion. Earnings were 265.00 million, an increase of 19.37%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for EVK stock is "Hold." The 12-month stock price target is €18.30, which is an increase of 2.46% from the latest price.
News
Evonik Industries AG: Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver
New GMP (good manufacturing practice) facility to meet increasing demand for lipid nanoparticle (LNP) development and clinical drug product manufacturingEvonik invests over 150 million CAD (93 mil...
Evonik Names Claus Rettig Interim CEO, Deputy Chair
BRUSSELS (dpa-AFX) - Evonik Industries AG (EVK.DE) announced on Thursday that Claus Rettig will serve as interim Chief Executive, while CEO Christian Kullmann recovers from an unplanned surgery. T...
Evonik Industries AG Earnings Call Transcript: Q2 2026
Q2 2026 saw a 24% year-over-year rise in adjusted EBITDA to €630 million, driven by strong Advanced Technologies and methionine performance. Workforce reductions and portfolio optimization continue, with an upgraded full-year outlook and robust cash generation supporting guidance.
Evonik Industries AG Slides: Q2 2026
Evonik Industries AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Evonik Industries AG Quarterly report: Q2 2026
Evonik Industries AG has published its Q2 2026 quarterly earnings report on August 4, 2026.
Evonik Industries AG Earnings release: Q2 2026
Evonik Industries AG released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Evonik Industries AG Slides: Company presentation
Evonik Industries AG has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Evonik Raises Guidance on Higher Prices, Cost Reductions
Evonik said it raised its guidance for the year on higher prices, higher sales volumes and cost reductions.
Evonik Industries AG Transcript: Investor update
Resilience, sustainability, and innovation are integrated to address global challenges and drive growth. Key initiatives include advanced biosolutions, green hydrogen, and circular economy solutions, supported by a restructured R&D organization and international hubs.
Evonik Industries AG Transcript: AGM 2026
The meeting addressed leadership changes, a challenging financial year, and a shift to a performance-based dividend policy. Strategic initiatives focus on innovation, cost discipline, and green transformation, with continued investment in growth areas.
Evonik Industries AG Earnings Call Transcript: Q1 2026
Q1 2026 adjusted EBITDA exceeded expectations at EUR 475 million, driven by strong Advanced Technologies and pre-buying effects, while free cash flow remained robust. Q2 EBITDA is guided to at least EUR 550 million, but risks from inflation and supply chain disruptions persist.
Evonik Industries AG Slides: Q1 2026
Evonik Industries AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 8, 2026.
Evonik Industries AG Quarterly report: Q1 2026
Evonik Industries AG has published its Q1 2026 quarterly earnings report on May 8, 2026.
Evonik Industries AG Earnings release: Q1 2026
Evonik Industries AG released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Evonik Industries AG Slides: Company presentation
Evonik Industries AG has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
Evonik Industries AG Earnings release: Q4 2025
Evonik Industries AG released its Q4 2025 earnings on March 4, 2026, summarizing the period's financial results.
Evonik Industries AG Annual report: Q4 2025
Evonik Industries AG has published its Q4 2025 annual report on March 4, 2026.
Evonik Industries AG Annual report: Q4 2025
Evonik Industries AG has published its Q4 2025 annual report on March 4, 2026.
Evonik Industries AG Slides: Q4 2025
Evonik Industries AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 4, 2026.
Evonik Industries AG Slides: Sustainability presentation
Evonik Industries AG has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Evonik Industries AG Slides: Investor presentation
Evonik Industries AG has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Evonik Industries AG Earnings Call Transcript: Q4 2025
Delivered solid 2025 results with EUR 1.9 billion adjusted EBITDA and strong cash flow. 2026 guidance targets stable earnings amid persistent weak demand, cost savings, and a new flexible dividend policy. Regulatory and market changes, especially in methionine and Oxeno, will shape performance.
Evonik Industries AG Earnings release: Q4 2025
Evonik Industries AG released its Q4 2025 earnings on February 5, 2026, summarizing the period's financial results.
Evonik Industries AG Slides: Q4 2025
Evonik Industries AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 5, 2026.
Evonik Industries AG Earnings Call Transcript: Q3 2025
Q3 results were weak, leading to a revised full-year EBITDA guidance of EUR 1.9 billion, but confidence remains in meeting targets due to strong healthcare and Animal Nutrition recovery. Structural cost savings, new plant ramp-ups, and the SYNEQT carve-out are expected to support future performance despite ongoing market challenges.